Pfizer sues over Accupril generic
Executive Summary
Newark, N.J. federal judge will hear arguments March 15 on Pfizer's request to preliminarily enjoin Teva and Ranbaxy from infringing an Accupril patent. Pfizer filed suit Jan. 28, alleging that the companies' generic quinapril infringes the patent. A court previously ruled that Teva's ANDA infringed, but Pfizer had not previously sued Ranbaxy. Teva began shipping quinapril manufactured under Ranbaxy's ANDA on Dec. 15 after Teva relinquished 180-day generic exclusivity rights (1"The Pink Sheet" Dec. 20, 2004, In Brief)...
You may also be interested in...
Teva/Ranbaxy launch Accupril generic
Teva/Ranbaxy launch first generic version of Pfizer's Accupril (quinapril) Dec. 15 following FDA approval of Ranbaxy's ANDA. The generic is being manufactured by Ranbaxy, with Teva handling distribution and marketing pursuant to an exclusive supply agreement between the companies. Teva relinquished its 180-day exclusivity, allowing FDA to approve Ranbaxy's ANDA; five other companies hold tentative ANDA approval. Court rulings finding Teva's ANDA infringed a valid Pfizer patent prevented Teva from bringing its own generic to market (1"The Pink Sheet" July 5, 2004, p. 11)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.